Introduction to Life Science REIT Plc Disclosures
Life Science REIT Plc stands at the forefront of the UK real estate investment trust sector, specializing in properties that cater to the life sciences industry. As part of its commitment to transparency, the company regularly releases detailed public disclosures that provide insights into its market positions, significant holdings, and other vital information.
Key Information on Disclosure
According to disclosure rules, companies must divulge significant holdings, especially by individuals or entities holding 1% or more of relevant securities. The full name of the discloser for Life Science REIT Plc is Rathbones Group Plc, responsible for maintaining the integrity and accuracy of these disclosures.
Ownership and Control Clarifications
When disclosing positions in Life Science REIT Plc, it's crucial to specify the direct ownership or control of interests and short positions. This information must be meticulously detailed to avoid ambiguity, ensuring compliance with market regulations.
Detailing Positions Held
Life Science REIT Plc has made it a priority to keep track of positions following any dealings. A comprehensive overview is typically provided, highlighting any relevant securities owned or controlled by major stakeholders within the company.
Relevant Securities Overview
At present, Rathbones Group Plc reports a significant ownership of approximately 48,803,541 shares in Life Science REIT Plc, equating to about 13.94% of the total ownership in this category of relevant securities. This figure represents a critical aspect of their market strategy and aligns with their commitment to maintaining transparency.
Dealing Activities
When it comes to dealing activities, any stock sales, purchases, or derivative transactions related to Life Science REIT Plc must be meticulously recorded. In a recent activity, for example, 15,630 shares were sold at a unit price of 37.58p. Such transactions underscore the importance of ongoing compliance and monitoring within the financial sphere.
Types of Derivative Transactions Recorded
Life Science REIT Plc also tracks cash-settled derivative transactions. Though there have been no recent cash-settled derivatives reported, the company remains vigilant about its investment instruments, ensuring all dealings adhere to regulatory standards.
Details on Indemnity and Dealing Arrangements
Transparency in dealings goes beyond just the transactions of securities; it also encompasses any indemnity or arrangement that may incentivize parties in dealings related to Life Science REIT Plc. As of now, no such arrangements have been identified, which highlights the commitment to open market practices.
Agreements Relating to Options and Derivatives
Formal understanding or agreements related to the voting rights of securities and derivatives are critical for stakeholders. Presently, there are no agreements that influence these rights or the acquisition/disposal of relevant securities noted for Life Science REIT Plc.
Contact Information for Further Inquiries
In case stakeholders need further clarification or have inquiries, Chinwe Enyi from the Compliance Department is available. You can reach out to her directly at 0151 243 7053. Clear communication lines are essential for addressing any concerns pertaining to disclosures and market positions.
Frequently Asked Questions
What is Life Science REIT Plc?
Life Science REIT Plc is a real estate investment trust focusing on life sciences real estate, providing properties and spaces for companies in this industry.
Why are disclosures important?
Disclosures ensure transparency in the markets, providing investors with critical information about ownership and control of securities, which influences market dynamics.
What are relevant securities?
Relevant securities refer to shares and other financial instruments that are openly held or controlled by significant stakeholders in the company.
How can I get in touch with the compliance department?
You can contact Chinwe Enyi at Life Science REIT Plc's Compliance Department for inquiries regarding disclosures.
What was the recent sale activity reported?
Recently, there was a sale of 15,630 ordinary shares at a price of 37.58p per unit, showcasing active trading within the company.
